Cover Image

Study of oxidative/nitrosative stress, non-enzymatic antioxidants and markers of airflow obstruction (fev1 % predicted) in chronic obstructive pulmonary disease (COPD) patients

Rupali S. Pawar*, Subhodhini A. Abhang, Damgaye T. M., Rahul Lokhande


Chronic Obstructive Pulmonary Disease (COPD) represents a major health problem. Its prevalence is increasing in worldwide. Oxidative stress is one of the major pathphysiologic hallmarks in the development of COPD. The aim of our study was to assess the relationship between the markers of oxidative / nitrosative stress (malondialdehyde and NO.) and the non-enzymatic antioxidants (vitamin E, vitamin C and GSH) with the marker of airflow obstruction (FEV1% predicted) in COPD patients. Study comprised of 185 stable COPD patients were divided into four stages according to GOLD guideline and 60 healthy controls were selected for the comparison. Pulmonary function test was done by using spirometer. Serum levels of MDA, NO., vitamin E, vitamin C and erythrocyte GSH were estimated by spectrophotometric method. Lung function tests namely FEV1/FVC% ratio and FEV1 % predicted showed significant reduction in COPD patients as compared to healthy controls. Serum level of MDA and NOshows increasing trend while serum levels of vitamin E, vitamin C and GSH shows decreasing trend across the stages of COPD. We found a significant negative correlation between NOand MDA with the FEV1%  predicted and positive correlation between vitamin C, vitamin E and GSH with FEV1% predicted in different stages of COPD patients. From this study we conclude that as the severity of disease increases FEV1 % predicted decreases. These changes are associated with an increase in oxidative/nitrosative stress and a concomitant decrease in non-enzymatic antioxidants in different stages of COPD patients studied.


FEV1 - Force Expiratory Volume in one second; FVC- Force Vital Capacity, GOLD - Global Initiative for Obstructive Lung Disease, GSH- Reduced Glutathione; MDA-Malondialdehyde; NO. - Nitric Oxide

Full Text:



GOLD, Global Initiative for chronic Obstructive Lung Disease management and prevention of chronic obstructive lung diseases, updated 2009, http://wwwgoldcopdcom.

Nadeem A, Raj HG and Chhabra SK. Increased oxidative stress and altered levels of antioxidants in Chronic Obstructive Pulmonary Disease Inflammation, 2005, 29,23-32.

Waseem SMA, Hussain MM, Zuber A, Naimul I. A study of pulmonary functions and lipid peroxidation biomarkers in COPD: Correlation between malondialdehyde and lung function. Biomed. Reser, 2012, 23(1), 66-71.

Sethi S, Mahler DA, Marcus P, Owen CA, Yawn B, Rennard S. et al., Inflammation in COPD : implications for management. Am J Med. 2012, 125(12), 1162-70.

Langen RCJ, Korn SH, Wonter EFM. Reactive oxygen species in the local and systemic pathogenesis of COPD. Free Radical Biol. Med. 2003, 35,226-35.

Hogg JC, Chu F, Utokaparch S, Woods R, Eliott WM. The nature of small –airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med.2004,350:2645-2653

Kinnula VL, Crapo JD. Superoxide dismutase in the lung and human lung diseases. Am. J. Respir. Crit. Care Med. 2003, 167, 1600-1619.

Joshi SR, Mehendale SS, Dangat KD, Kilari AS, Yadav HR, Taralekar VS. et al., High maternal plasma antioxidant concentration associated with preterm delivery . Ann. Nutr. Metab. 2008, 53,276-82.

Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L- arginine. Nature.1988,333,664

Barnes PJ, Belvisi MG. Nitric oxide and lung disease. Thorax.1993, 48,1034-43

Mccall TB, Broughton SNK, Palmer RMJ, Whittle BJR, Moncada S. Synthesis of nitric oxide from L-arginine by neutrophil release and interaction with superoxide anions. Biochem. J. 1989, 261,293-8.

Stamler JS, Singal DJ, Loscalzo J. Biochemistry of nitric oxide and its redox activated forms. Science.1992, 258, 1898-902.

Halliwell B, Gutteridge JC. The definition and measurement of antioxidants in biological systems. Free Radic.Biol. Med.1995,18,125-126

Bilacom HMO, Grant BJB, Muti P, Sempos CT, Frendenheim JL, Browne RW, Mccann SE, Trevison M, Cassano PA, Iacoviello L, Schunemann HJ. Antioxidant, oxidative stress and pulmonary function in individuals diagnosed with asthma or COPD. European J. Clin. Nutri.2006, 60,991-999.

Packer JE, Slater TF, Wilson RL. Direct observation of a free radical interaction between vitamin E and vitamin C. Nature.1979, 278, 737-38.

Thomas CE, Mclean LR, Porker RA, Ohlweiler DF. Ascorbate and phenolic antioxidant interaction in prevention of liposomal oxidation. Lipids .1992, 27,543-50.

Scarpa M, Rigo A, Maiorino M, Ursini F, Gregolin C. Formation of alpha-tocophrol radical and recycling of alpha –tocopherol by ascorbate during peroxidation of phosphotidylcholine liposome. Biochim. Biophys. Acta. 1984,801,215-92.

Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem Biol. Interact. 1998,111-2,1-1.

Cantin AM, Begin R. Glutathione and inflammatory disorders of lung.Lung.1991, 169(3), 123.

Cross CE, Vander A, Vliet CA, Neill O, Louie S, Halliwell B et al., Oxidant antioxidants and respiratory tract lining fluids. Environ. Health Prospect. 1994, 102,185-191.

Hagen TM, Brown LA, Jones DP. Protection against paraquat-induced injury by exogenous GSH in pulmonary alveolar type II cells. Biochem. Pharmacol. 1986, 35, 4537-4542.

Shi M, Gozal E, Choy HA, Forman HJ. Extracellular glutathione and γ-glutamyl transpeptidase prevent H2O2-induced injury by 2, 3 dimethoxy-1, 4-napthoquinone. Free Radic. Biol. Med. 1993, 15, 57-67.

Tsan MF, White JE, Rosano CL. Modulation of endothelial GSH concentration effect of exogenous GSH & GSH monoethyl ester. J Appl. Pysio. 1989, 66, 1029-1034.

MacNee W, Rahman I. Oxidant and antioxidants as therapeutic targets in COPD. Am. J. Respir. Crt. Care Med. 1997, 160,’S’ 58-65.

MacNee W. Pulmonary and systemic oxidant / antioxidant imbalance in COPD. Am. Thorac Soc. 2005, 2, 50-60.

Buege JA, Aust SD. Microsomal lipid peroxidation. Method Enzymol.1978, 52,302-310.

Cortas NK, Wakid W. Determination of inorganic nitrate in serum and urine by kinetic cadmium – reduction method. Clin. Chem. 1990, 3618, 1440-1443.

Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J.Lab.Clin. Med.1963, 61(5), 882-888.

Ayeqyaw. A simple colorimetric method for ascorbic acid determination in blood plasma. Clinica Chemica Acta. 1996, 86,153-157.

Baker, Frank. Determination of vitamin E level in serum. Meth. Enzymo.1968, 172.

Paul K, Rahman I. Oxidative stress in asthma and COPD: Antioxidant as atherapeutic stategy. Pharmacology and Therapeutics.2006, vol.1, issue 2, 476-494.

John ER, Aalt B,Ida L.Oxidative stress in chronic obstructive pulmonary disease. Am.J.Respir.Crit. Care. Med. 1997, 156(2), 341-57.

Thomason MJ, Strachan DP. Which spirometric indices best predict subsequent death from chronic obstructive pulmonary disease? Thorax. 2000, 55, 785-8.

Daphne CR, Jame RJ, Nell H, Mae MS, Elvism I. Diagnostic value of post bronchodilator pulmonary function testing to distingwish between stable moderate to severe COPD and asthma. Intr. J. COPD. 2008, 3(4), 693-699.

Richter C, Gogvadze V, Laffranchi R, Sclapbach R,Schweizer M, Suter al., Oxidant in mitochondria from physiology to diseases. Biochem Biophys. Acta., 1995,1271,67-74.

Papaioannoou AI, Mazioti A, Kiropoulos T, Tsilioni I, Kotsokera A, Tanou K et al., Systemic and airway inflammation and presence of emphysema in patients with Chronic Obstructive Pulmonary Disease. Respir. Med. 2010, 104, 275-282.

Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L et al., Association between markers of emphysema and more severe Chronic Obstructive Pulmonary Disease. Thorax. 2006, 61, 1037-1042.

Daga MK, Chhabra R, Sharma B, Mishra TK. Effects of exogenous vitamin E supplementation on the levels of oxidant and antioxidants in Chronic Obstructive Pulmonary Disease. J Biosci. 2003, 28(1), 7-11.

Kirkil G, Muz. MH, Seckin D, Sahin K, Kucuk O. Antioxidant effect of Zinc picolinates in patients with Chronic Obstructive Pulmonary Disease. Respir. Med. 2008, 102,840-844.

Isik B, Isik SR, Yolacan H, Isik MR. Serum Malondialdehyde and Paraoxonase levels in Chronic Obstructive Pulmonary Disease. Turkish Respir. J. 2005, 6(1), 19.

Lee SI. The levels of antioxidant enzyme in red blood cells of patients with chronic obstructive pulmonary disease. Tuberculosis& Respiratory Disease.1994, 104, 44.

Rehman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD and smokers. Am.J. Respir. Crit. Care Med. 1996, 154, 1055-60.

Yessica D, Torres R, Maria L, Guillen G, Ivonne M ,Corichi O, Hicks JJ. Correlation of plasma protein carbonyl and C-reactive protein with GOLD stage progression in COPD patients. The Open Respir. Medi. J.2009, 3, 61-66.

Menon B, Pandita S. Evaluation of oxidant-antioxidant status in different stages of COPD: determination of serum paraoxonase1 and MDA levels. Eur. J Res.2012, 23(1), 66-71.

Rout A, Suryakar AN. Study of oxidative stress relation with antioxidant status in chronic bronchitis. Intr. J.Public Health Sci., 2012, vol1, no1, pp7-10.

Kanazawa, Shoji, Yoshikawa, Hirata. Increased production of endogenous nitric oxide in patients with bronchial asthma and COPD. Clinical and Experimental Allergy.1998, vol.28, issue 10, pg no.1244-1250.

Tier KP, Ziani JM, Aubourg F, Cabane J, Dinh AT. Diagnostic value of exhaled nitric oxide to detect interstitial lung disease in systemic sclerosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2009,26,32-38.

Schunemann HJ, Muti P, Freudenheim JL. Oxidative stress and pulmonary function. Am. J Epidemiol. 1997, 146,939-48.

Arpana V, Ehtesham A, Deepak D, Sing B, Pasha MA. Correlation of oxidative stress with BMI and lung function in COPD. Clinical Biochem. 2007,40,958-963.

Ahmad A, Shameem M, Husain Q. Correlation of exhaled carbon monooxide and nitric oxide with airflow obstruction in asthma and chronic obstructive pulmonary disease patients. Annals 0f Biological Reaserch. 2012, 3(4), 1672-1678.

Calikoglu M, Tamer L, Calikoglu I, Atis S, Ulubas B,Ercan al. Oxidative stress and product of nitric oxide metabolism in chronic obstructive pulmonary disease and in healthy smokers.Turkish Respiratory Journal 2002,3(1),24-27.

Haffner JE, Repin JE. Antioxidants and the lung. The Lung: Scientific foundation. New York: Raven Press. 1991, p1811-20.

Toorn MV, Maria P, Varies S, Slebos D, Bruin HG, Abello N, et al., Cigarette smoke irreversibly modifies glutathione in airway epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2007, 293, L1156-L1162.

Nagaraj, Pyati A, Murthy S. Oxidative stress and antioxidant status in COPD patients. Intr. J of Pharm. and Biol. Sci. 2011, vol 1, issue4, 447-456.

Heunks LM, Dekhuijzen PN. Respiratory Muscle function and free radicals from cell to Chronic Obstructive Pulmonary Disease. Thorax. 2000,55,704-716.

Heffner JE, Repin JE. Pulmonary strategies of antioxidant defense. Am. Rev. Respir. Dis. 1989, 140,531-554.

Sargeant LA, Jaeckel A, Wareham NJ. Interaction of vitamin C with the relation between smoking and obstructive airway disease in EPIC Norfolk. Eur. Respir. J. 2000, 16:397-403.

Rai RR, Phadke MS. Plasma oxidant-antioxidant status in different respiratory disorders. Indian J Clin. Biochem. 2006, 21(2), 161-164.

Calikoglu M, Unlu A, Tamer L, Ercan B, Bugdayci R, Atik U et al., The levels of serum vitamin C, malondialdehyde and erythrocyte reduced glutathione in Chronic Obstructive Pulmonary Disease and in healthy smokers. Clin. Chem. Lab. Med. 2002, 40(10), 1028-1031.

Schwatz J, Weiss ST. Relationship between dietary vitamin C intake and pulmonary function in first National Health and Nutritional Survey (NHANESI). Am. J.Clin.Nutr.1994, 59,110-114.

Jadhav BS, Bardapurkar JS, Bhagwat VR, Bardapurkar SJ. Vitamin E and FEV1% correlation Evaluation of total serum alpha-1-antitrypsin and vitamin E in smoker and non-smoker chronic obstructive pulmonary disease patients. Biomedicine.2013, 33(4), 520-525.



  • There are currently no refbacks.

Copyright (c) 2014 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.